Choosing a needle for a subcutaneous peptide

The most important measurement in injection technique is the thickness of human skin, and it is smaller and more consistent than almost anybody expects. Ultrasound studies across large adult populations put skin thickness at the abdomen, thigh, upper arm and buttock at roughly two to two and a half millimetres, with remarkably little variation by body mass index. Subcutaneous fat varies enormously; the layer above it does not. A needle of four millimetres therefore clears the dermis reliably and lands in subcutaneous tissue in essentially every adult, which is why the recommendations moved to short needles and why the market has been slow to follow.

Needle length and the two millimetres that matter

Ultrasound measurement across large adult populations puts skin thickness at the four standard injection sites at roughly 1.9 to 2.4 millimetres, with surprisingly little variation by body mass index, sex or ethnicity. Subcutaneous fat thickness varies by a factor of many; the layer above it barely varies at all.¹

That finding is why needle-length recommendations moved decisively toward short needles. A 4 mm needle inserted perpendicular clears the dermis in essentially all adults and deposits into subcutaneous tissue, and comparative trials of 4 mm pen needles found glycaemic control and safety equivalent to longer needles with better patient ratings.² The published injection-technique recommendations that followed endorse 4 mm as adequate for adults regardless of body size.³

The persistence of 12.7 mm needles in the research-peptide market is therefore habit rather than reasoning, and it is not a harmless habit. A longer needle in a lean thigh or arm can traverse the subcutaneous layer and deliver intramuscularly, which changes the absorption profile of a preparation designed as a subcutaneous depot. The correct response to uncertainty about depth is a shorter needle, not a longer one.

Gauge, angle and whether to pinch

Gauge describes bore: higher numbers are thinner. Insulin syringes are commonly twenty-nine to thirty-one gauge and pen needles run to thirty-two or thirty-four. Thinner needles are more comfortable and flow more slowly. For an aqueous peptide solution the flow penalty is minor; for anything viscous it becomes real, and the practical failure is that people push harder and lose control of the plunger.

Angle and skin-pinch technique follow from length. With a 4 mm needle, insertion perpendicular to the skin without a pinch is appropriate, because there is no plausible way to reach muscle. With longer needles a lifted skin fold is required in order to raise the subcutaneous layer away from muscle, and the fold must be released only after the needle is withdrawn — releasing early while the needle is in situ defeats the purpose.³

The habit of injecting at forty-five degrees is a legacy of long needles and is a poor default with short ones, because an oblique 4 mm track can end intradermally. The Journal states the simple version: short needle, ninety degrees, no pinch, and there is then very little left to get wrong about depth.

Accidental intramuscular delivery

Intramuscular delivery of a subcutaneous preparation accelerates and destabilises absorption. The insulin literature established this cleanly: intramuscular administration produces faster onset and markedly greater between-occasion variability than subcutaneous administration of the same preparation.⁴

For a weekly acylated agonist the consequences of one such injection are less acute than for a mealtime insulin, because the depot is designed to release over days and albumin binding dominates the kinetics. It is nonetheless an unintended change in the input function, and where it happens repeatedly — a long needle used consistently in a lean thigh — it becomes a persistent alteration in exposure that no dose adjustment will explain.

The signals are not reliable. A deeper ache during and after injection, more bleeding, and a sensation of the injection being harder to push are all suggestive and none are diagnostic. This is why the answer is structural rather than perceptual: a 4 mm needle removes the possibility, and no amount of attentiveness makes a 12.7 mm needle in a lean thigh safe from it.

Storage, and the in-use period nobody can give you

Lyophilised peptide is generally stored refrigerated at two to eight degrees, and is considerably more stable dry than in solution — which is the entire reason it is supplied as a powder. After reconstitution, degradation proceeds by hydrolysis, oxidation, aggregation and adsorption to container surfaces, at rates depending on sequence, buffer, temperature, light exposure and headspace.⁵

For licensed products the in-use period is established by formal stability testing and printed on the carton, commonly twenty-eight days for a pen in use. For a peptide reconstituted at home there is no such study, and the numbers circulating in this market are extrapolations from other molecules, other buffers and other containers.

Three practical points survive that uncertainty. Cold slows every degradation route, so refrigeration is unambiguously better than ambient storage. Agitation promotes aggregation, so a vial should be swirled or the diluent run down the wall rather than shaken. And repeated temperature cycling — out for a dose, back in the door of the fridge, out again — is worse than steady cold, which argues against storing a vial in the door.

Anybody quoting a precise expiry for a home-reconstituted peptide is quoting a guess. The Journal would rather say so than repeat a number that sounds authoritative.

The arithmetic is only as good as the label

Every calculation above starts from a stated mass of peptide in the vial. For licensed product that figure is a release specification. For research-grade lyophilised powder it is a claim, and the difference matters because the claim sits at the front of every subsequent computation.

Two distinct quantities are involved. Chromatographic purity is the proportion of peptide-related material that is the intended peptide. Peptide content is the fraction of the vial mass that is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain materially less peptide than labelled, and content is the number that determines a dose.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content less consistently. Several vendors, among them WXT, SSA, CPC, SWB and MKM, publish per-batch reports; others publish nothing verifiable. Where content has not been measured, the labelled mass should be treated as an upper bound and the resulting dose figure as an estimate. That is unsatisfying and it is honest, and it is why the Journal has argued in Analytics for content and endotoxin as standard reported fields.

How the Journal reports technique

Two bodies of evidence underlie this file. Questions of tissue, depth, needle length and rotation come from the insulin injection-technique literature, which is large, well conducted and directly transferable because it concerns anatomy rather than any particular molecule. Questions of absorption by site, in-use stability and exposure come from the incretin literature, which is smaller and where we say so. Where we describe practice rather than evidence, the text states it.

We give arithmetic in full rather than in tables of pre-computed unit counts, deliberately. A pre-computed table is correct only for the concentration it was computed for, and the recurring error in this market is precisely the reuse of a correct number under changed conditions. A reader who can perform the four-line calculation is protected against a class of error that no table can prevent.

Nothing in this file is medical advice. The Journal does not recommend doses, products, diluents or suppliers, and cannot assess an individual. Several compounds discussed are sold for research use only, are not approved for human use in any jurisdiction, and are not manufactured or released to any human sterility, content or endotoxin standard. Injection technique is properly taught in person by a clinician or nurse, and this file is not a substitute for that.

A short glossary

Unit (U-100): ten microlitres. A volume, not an amount of drug. Concentration: mass per volume, here usually milligrams per millilitre. Dead space: volume retained in needle and hub after full depression of the plunger. Priming: expelling a small volume before dosing, to clear air and confirm flow.

Gauge: needle bore, inversely numbered — higher gauge is thinner. Subcutaneous: into the fat layer beneath the dermis. Intradermal: within the skin itself, which is what an oblique short needle risks. Intramuscular: into muscle beneath the subcutaneous layer.

Lipohypertrophy: thickened subcutaneous tissue from repeated injection, with blunted and variable absorption. Lipoatrophy: localised loss of subcutaneous fat, a different and now rare immune-mediated phenomenon. Bacteriostatic: inhibiting microbial growth, not sterilising. In-use period: the interval after first puncture during which a product remains within specification, established by stability testing.

The distinction between bacteriostatic and sterile, and the distinction between purity and content, account between them for a large share of the confused correspondence this desk receives.

Our practical conclusion is that the useful defences here are structural rather than attitudinal. Write the concentration on the vial. Recalculate at every new vial. Keep one syringe type. Change one variable at a time. Exhortations to be careful do not survive a bad week; a number written in marker on a piece of tape does.